Dr. Peter J. Piliero, Executive Director and Medical Leader, Boehringer Ingelheim Pharmaceuticals, Inc.
Genre: News Videos
by: comments
Today ten people with diabetes from across the U.S. and as far as South America were honored for their moving portrayal of how this chronic condition impacts their everyday life through the Making Sense of Diabetes online video contest. A compilation of the winning videos premieres at MakingSenseofDiabetes.org to mark the importance of World Diabetes Day on November 14th. The contest was sponsored by the Diabetes Hands Foundation, a pioneering advocacy organization in social media, and made possible through support provided by Boehringer Ingelheim Pharmaceuticals, Inc.To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/boehringeringelheim/40997/
Dr. Sarah Jarvis Richford Gate Medical Practice London UK, comments on the importance of tolerabilty in CVD treatment The results of the TRANSCEND® trial demonstrate that telmisartan 80mg reduces the risk of cardiovascular death, myocardial infarction/heart attack and stroke in high-risk cardiovascular patients by 13% compared with those patients already receiving best standard of care (p=0.048), referring to the same endpoint as that defined as the primary endpoint of the landmark HOPE trial published in 2000.1,2 Therapy with telmisartan was well tolerated and showed a trend towards a lower rate of discontinuation.1 The new data on 5,926 patients from 40 countries were presented today at the annual congress of the European Society of Cardiology (ESC) in Munich, Germany. TRANSCEND®* is the first landmark trial to test and prove the cardiovascular protective effects of an angiotensin II receptor blocker (ARB) – Boehringer Ingelheim's telmisartan – versus placebo, on top of standard therapy ...
Prof. Peter Sleight Dept of Cardiovascular Medicine Oxford, UK, comments on the outcome of the TRANSCEND trial The results of the TRANSCEND® trial demonstrate that telmisartan 80mg reduces the risk of cardiovascular death, myocardial infarction/heart attack and stroke in high-risk cardiovascular patients by 13% compared with those patients already receiving best standard of care (p=0.048), referring to the same endpoint as that defined as the primary endpoint of the landmark HOPE trial published in 2000.1,2 Therapy with telmisartan was well tolerated and showed a trend towards a lower rate of discontinuation.1 The new data on 5,926 patients from 40 countries were presented today at the annual congress of the European Society of Cardiology (ESC) in Munich, Germany. TRANSCEND®* is the first landmark trial to test and prove the cardiovascular protective effects of an angiotensin II receptor blocker (ARB) – Boehringer Ingelheim's telmisartan – versus placebo, on top of standard therapy (including ...
Genre: Entertainment
